Macrophage-targeted glucocorticoid prodrug resolves acute inflammation while preserving HPA axis function: mechanistic, preclinical, and Phase II/III clinical evidence

Glucocorticoids (GCs) remain the fastest-acting anti-inflammatory agents but are constrained by systemic exposure that suppresses the hypothalamic–pituitary–adrenal (HPA) axis, silences adaptive immunity, and drives chronic toxicities. Chronic inflammatory diseases are sustained by long-lived CD206⁺ macrophages containing immune-resistant pathogenic material not cleared physiologically. We developed 101-PGC-005 (’005), a macrophage-targeted type 1a dexamethasone prodrug engineered for low-affinity, recycling-compatible uptake via CD206, with intracellular release triggered by acidic endosomes.

We evaluated ’005 in mechanistic assays, pathogen-diverse preclinical models, three human pharmacokinetic (PK) studies, and an adaptive-design randomized Phase II/III trial in 309 hospitalized patients with moderate COVID-19. In two completed Phase I human studies — a first-in-human dose-escalation and repeated-dose study and a dedicated single-/multiple-dose PK and safety study — ’005 circulated as intact prodrug with rapid systemic clearance (Tmax ∼0.5 h; terminal half-life ∼1.9 h), with no measurable free dexamethasone after single dosing and only low, clinically non-significant free dexamethasone after repeated dosing, and intact prodrug recovered unchanged in urine. Morning cortisol and ACTH were preserved after 30 mg once daily for three consecutive days (1.5× the intended therapeutic dose). A cerebrospinal fluid PK study is evaluating central-compartment penetration.

In the Phase II/III trial — powered for non-inferiority, conducted across six sites in India under GCP with Ministry of Health approval and independent DSMB oversight — ’005 (20 mg IV daily × 3 days) was superior to dexamethasone (6 mg IV daily × 3–10 days) on the primary endpoint of time to ≥2-point improvement on the WHO ordinal scale (HR 2.31; 95% CI 1.83–2.93; p < 0.0001; median 3 vs. 4 days). ’005 was also superior on viral clearance (HR 1.47; 95% CI 1.17–1.84; p = 0.0001), hospital discharge rate, SpO₂ recovery, and fever resolution. Zero patients in the ’005 arm received investigator-initiated corticosteroid supplementation despite protocol allowance. All 309 randomized patients completed the study (ITT = per-protocol). Safety profiles were equivalent (TEAEs 54.8% vs 54.5%; p = 0.958), with no Grade 3+ events, SAEs, deaths, or discontinuations in either arm.

Mechanistically, ’005 delivered dual benefit: acute debulking of inflammatory macrophages and selective depletion of chronically activated pathology-sustaining macrophages, while preserving CXCL10 antiviral signaling and physiologic HPA control. Critically, HPA preservation is not merely a safety feature — it is a core efficacy mechanism: by clearing the pathogenic macrophage burden that was overriding HPA regulation, ’005 restores the conditions for endogenous cortisol to resume its pulsatile, demand-responsive anti-inflammatory role across all GR-expressing cells — lymphocytes, endothelial cells, neurons, and newly differentiated macrophages — that ’005 itself cannot reach. These findings support regulatory-grade evidence for macrophage-targeted corticosteroid therapy and provide the foundation for further development across acute inflammatory indications (sepsis, viral pneumonia, cytokine-release syndromes) and chronic macrophage-driven diseases (atherosclerosis, metabolic steatohepatitis, neurodegeneration, tumor-associated macrophages).

One Sentence Summary

A macrophage-targeted dexamethasone prodrug achieves superiority over standard-of-care dexamethasone across two replicate randomized controlled trials totaling 309 patients, without suppressing the hypothalamic–pituitary–adrenal axis.